4
Changes in Ownership
MoonLake Immunotherapeutics Filed Acc 0001213900-23-028294
Chief Financial Officer acquired 557,931 shares (conversion)
- Chief Financial Officer returned 557,931 shares (to the company)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bodenstedt Matthias Chief Financial Officer | 2023-04-05 | Conversion | +410,796 | 410,796 | D | ||
| Bodenstedt Matthias Chief Financial Officer | 2023-04-05 | Returned to the company | −410,796 | 0 | D | ||
| Bodenstedt Matthias Chief Financial Officer | 2023-04-05 | Conversion | +147,135 | 557,931 | D | ||
| Bodenstedt Matthias Chief Financial Officer | 2023-04-05 | Returned to the company | −147,135 | 357,445 | D | ||
| Derivatives | |||||||
| Bodenstedt Matthias Chief Financial Officer | 2023-04-05 | Conversion · Common shares, par value CHF 0.10 per share, of MoonLake AG | −12,212 | 0 | D | ||
| Bodenstedt Matthias Chief Financial Officer | 2023-04-05 | Conversion · Common shares, par value CHF 0.10 per share, of MoonLake AG | −4,374 | 10,626 | D | ||
Loading xslF345X04/ownership.xml…